Trials / Active Not Recruiting
Active Not RecruitingNCT05050097
A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
A Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 166 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to characterize the safety and tolerability of talquetamab when administered in different combination regimens and to identify the safe dose(s) of talquetamab combination regimens.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Talquetamab | Talquetamab will be administered subcutaneously. |
| DRUG | Carfilzomib | Carfilzomib will be administered as an IV infusion. |
| DRUG | Daratumumab SC | Daratumumab will be administered subcutaneously. |
| DRUG | Lenalidomide | Lenalidomide will be self-administered orally. |
| DRUG | Pomalidomide | Pomalidomide will be self-administered orally. |
Timeline
- Start date
- 2021-09-22
- Primary completion
- 2025-03-31
- Completion
- 2027-04-07
- First posted
- 2021-09-20
- Last updated
- 2026-04-13
Locations
31 sites across 6 countries: United States, Australia, Belgium, France, Netherlands, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05050097. Inclusion in this directory is not an endorsement.